Advancing NGS bioinformatics analysis in Precision Oncology in Europe through the Instand-NGS4P project
1. Introduction
The Instand-NGS4P* initiative is a groundbreaking effort to optimize Next-Generation Sequencing (NGS) for clinical diagnostics, revolutionizing precision oncology workflows across Europe. As part of this initiative, Genomate Health, Euformatics, and BC Platforms have joined forces to create a fully integrated and standardized reporting solution for molecular diagnostics. The joint EU-Onco-Platform solution has been awarded throughout the 3 phases of this pre-commercial procurement (PCP) process and tested by 3 leading European hospitals.
With 3 years of joint R&D effort between leading precision oncology innovators, and supported by over €1.1 million in funding from the Instand-NGS4P consortium**, this collaborative solution ensures that oncologists and molecular pathologists can seamlessly interpret genomic data, enabling faster, more accurate treatment decisions for cancer patients. The strategic goal? A frictionless, interoperable, and clinically actionable precision oncology ecosystem for European hospitals and diagnostic laboratories.
* The project is co-funded by the European Union Grant Agreement number 874719.
** The consortium is formed by hospitals from the Medical University of Graz in Austria, University of Florence and University of Milano-Bicocca in Italy, Erasmus University Medical Center in the Netherlands, Christian-Albrecht University of Kiel and St. Anna Children’s Cancer Research Institute in Germany, and the Centre Léon Bérard in France.
2. Solution Highlights
At the core of our solution are two mature, market-tested software systems: Euformatics’ omnomicsNGS, delivering end-to-end NGS reporting from VCF to structured clinical reports, and Genomate Health’s digital drug assignment module, offering advanced therapeutic insights. Through this project, both platforms have been enhanced—new features have been added, oncology-specific tailoring implemented, and seamless integration established to deliver a truly market-ready, interoperable product. The result is a unified, API-driven ecosystem that bridges molecular data and clinical decision-making with ease.
Key features include:
✅ Streamlined clinical workflows: Enabling hospitals to efficiently analyze, interpret, and act on molecular profiling results without additional IT complexity.
✅ Automated processes: Eliminating manual data entry and reducing the risk of errors in variant interpretation and reporting.
✅ Accelerated turnaround time: Advanced automation and integration minimize delays in reporting, bringing actionable results to clinicians faster than ever before.
✅ Next-generation molecular tumor board (MTB) support: The digital drug assignment module provides a standardized framework with predicted drug efficacy
Additional highlights:
✅ Compliance: Our solution aligns with industry standards for clinical validation and security.
✅ Sustainability & Future-Proofing: Designed to support long-term clinical adoption, with scalable architecture and continued innovation in NGS-based oncology reporting.
3. Proven Success: Hospital Deployments and Positive Feedback
The EU-Onco-Platform reporting solution has been tested across 3 European hospitals* as part of the Instand-NGS4P initiative with an overall score of 4.2/5. Feedback from clinicians and institutions highlights:
- “Fully compatible with various VCF formats.” – UNIFI
- “The identified variants have been correctly annotated and the nomenclature is compliant with the most recent guidelines.” – UNIFI
- “Tables can be downloaded in multiple formats (Excel, CSV, HTML).” – CCRI
- “Very supportive instructions by virtual and on-site meetings.” – UKSH
- “This tool can improve reporting of NGS analysis for both liquid biopsy and PGx panels.” – UNIFI
- “Good level of innovation in the use of AI-based variant characterization and automatic report generation.” – UNIFI
- “The report was well structured and usable to a clinician, with valuable classification based on clinical evidence.” – UNIFI
- “Most important findings from routine analysis were also identified with this solution.” – CCRI
- “Genomate drug prioritization is very innovative.” – CCRI
4. Continued Collaboration
Genomate Health and Euformatics are proud to continue their successful collaboration, extending their joint offering beyond the original project scope. In response to requests from clinical sites, testing and pilot use of the solution are ongoing. The partnership is also advancing through new initiatives, including participation in another PCP (oncNGS), a running Eurostars project, and a recently submitted EP PerMed application—demonstrating a shared commitment to driving innovation in precision oncology.
5. About the vendors
Euformatics
Euformatics is a Finnish software company that specializes in high-standard bioinformatics tools for genomic data interpretation. Since 2010, Euformatics has been helping medical doctors and molecular genetics laboratories provide better precision medicine for cancer and common or rare disease diagnostics. At present, our core solution is the Genomics Hub which includes a variant interpretation tool; for clinical analysis and reporting of patient NGS data and a quality control tool; for NGS data quality management.
🌐 Website: euformatics.com
📧 Email: contact@euformatics.com
Genomate Health
Genomate Health is at the forefront of standardizing precision oncology across the globe, ensuring that personalized decisions are both clinically effective and operationally scalable.
Genomate Health is redefining precision oncology with its IT-powered digital drug assignment system, a cutting-edge solution that automates and optimizes treatment selection for cancer patients. By leveraging comprehensive molecular profiling, the platform evaluates all detected tumor alterations and ranks EMA- and FDA-approved therapies, as well as relevant drugs in clinical trials, based on predicted efficacy. The system seamlessly integrates with Euformatics’ omnomicsNGS via a one-click API, ensuring frictionless interoperability with genomic reporting workflows. Clinically validated using SHIVA trial data, the system has demonstrated a correlation between predicted drug efficacy and patient outcomes, reinforcing its potential as a reliable clinical decision-support tool. By guiding oncologists toward the most effective, personalized treatment strategies, Genomate’s solution has the potential to significantly improve patient survival.
🌐 Website: genomate.health
📧 Email: info@genomate.health
BC Platforms
BC Platforms is a global leader in providing a powerful data and technology platform for personalized medicine and drug development, accelerating the translation of insights into clinical practice. Our technology drives the infinite loop between personalized care and research discoveries, leveraging latest science, deep technical expertise, strategic partnerships, and harmonized, diverse data collections. Our high performing genomic data discovery and analytics platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information.
🌐 Website: bcplatforms.com
📧 Email: info@bcplatforms.com
6. About Instand-NGS4P
Instand-NGS4P is a 65-month PCP project federating 7 leading medical centers (two are coordinating ERNs) as buyers’ groups with major experience in using different NGS platforms in research and routine diagnostics. The consortium is further strengthened by European patient advocacy groups, a standardization organization and partners participating in the European infrastructures BBMRI-ERIC, ELIXIR as well as several NGS-related EU programs to cover all technical aspects and transversal needs & requirements.
For more information, please visit the website www.instandngs4p.eu
7. Get Involved: Future Collaborations & Next Steps
Join us in shaping the future of precision oncology. Contact us to explore collaborations, hospital deployments, and next-generation integrations.
Let’s empower clinicians, accelerate precision medicine, and improve patient outcomes—together!
